Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2004 Jul 21

PMID 15260935

Citations 1

Authors

F M E Wagenlehner

K G Naber

Affiliations

Soon will be listed here.

Abstract

Chronic bacterial prostatitis is the most frequent cause for recurrent urinary tract infection in young and middle-aged men. The selection of an appropriate antimicrobial agent that has optimal pharmacokinetics for urine and prostatic secretion and tissue is important in both entities. Fluoroquinolones possess several pharmacologic characteristics that favor them for treatment of urinary tract infection and prostatitis. The pharmacokinetics of fluoroquinolones and the theoretical background of drug penetration into the prostate are outlined. Analyzing the concentrations of various fluoroquinolones in urine, prostatic and seminal fluid, and in prostatic tissue, it becomes obvious that the fluoroquinolones differ in plasma concentrations and in their concentrations at these sites. Nevertheless, overall, the concentrations at the site of infection of most of the fluoroquinolones should be sufficient for the treatment of chronic bacterial prostatitis and vesiculitis and recurrent urinary tract infection in men caused by susceptible pathogens.

Citing Articles

Phage Therapy Related Microbial Succession Associated with Successful Clinical Outcome for a Recurrent Urinary Tract Infection.

Terwilliger A, Clark J, Karris M, Hernandez-Santos H, Green S, Aslam S Viruses. 2021; 13(10).

PMID: 34696479 PMC: 8541385. DOI: 10.3390/v13102049.

References

Drlica K, Zhao X . DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61(3):377-92. PMC: 232616. DOI: 10.1128/mmbr.61.3.377-392.1997. View

Stamey T, Meares Jr E, Winningham D . Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol. 1970; 103(2):187-94. DOI: 10.1016/s0022-5347(17)61919-0. View

Naber C, Steghafner M, Kinzig-Schippers M, Sauber C, Sorgel F, Stahlberg H . Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother. 2000; 45(1):293-7. PMC: 90275. DOI: 10.1128/AAC.45.1.293-297.2001. View

Biering-Sorensen F, Hoiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V . Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol. 1994; 151(1):105-8. DOI: 10.1016/s0022-5347(17)34882-6. View

Naber K, Sorgel F, Kinzig M, Weigel D . Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol. 1993; 150(5 Pt 2):1718-21. DOI: 10.1016/s0022-5347(17)35877-9. View

Pust R, Ackenheil-Koppe H, Gilbert P, Weidner W . Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results. J Chemother. 1989; 1(4 Suppl):869-71. View

Ulleryd P, Sandberg T . Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003; 35(1):34-9. DOI: 10.1080/0036554021000026988. View

Pfau A, Perlberg S, Shapira A . The pH of the prostatic fluid in health and disease: implications of treatment in chronic bacterial prostatitis. J Urol. 1978; 119(3):384-7. DOI: 10.1016/s0022-5347(17)57497-2. View

Naber K, Kinzig M, Sorgel F, Weigel D . Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection. 1993; 21(2):98-100. DOI: 10.1007/BF01710740. View

10.

de la Rosette J, Hubregtse M, Meuleman E, Debruyne F . Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology. 1993; 41(4):301-7. DOI: 10.1016/0090-4295(93)90584-w. View

11.

Litwin M, McNaughton-Collins M, Fowler Jr F, Nickel J, Calhoun E, Pontari M . The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999; 162(2):369-75. DOI: 10.1016/s0022-5347(05)68562-x. View

12.

Schaeffer A . Prostatitis: US perspective. Int J Antimicrob Agents. 1999; 11(3-4):205-11; discussion 213-6. DOI: 10.1016/s0924-8579(99)00046-1. View

13.

Lipsky B . Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med. 1989; 110(2):138-50. DOI: 10.7326/0003-4819-110-2-138. View

14.

Naber K, Giamarellou H . Proposed study design in prostatitis. Infection. 1994; 22 Suppl 1:S59-60. DOI: 10.1007/BF01716050. View

15.

Vorland L, Carlson K, Aalen O . An epidemiological survey of urinary tract infections among outpatients in Northern Norway. Scand J Infect Dis. 1985; 17(3):277-83. DOI: 10.3109/inf.1985.17.issue-3.06. View

16.

Naber K, Bergman B, Bishop M, Botto H, Lobel B, Jinenez Cruz F . EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol. 2001; 40(5):576-88. DOI: 10.1159/000049840. View

17.

Bjerklund Johansen T, Gruneberg R, Guibert J, Hofstetter A, Lobel B, Naber K . The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 1998; 34(6):457-66. DOI: 10.1159/000019784. View

18.

Krieger J, Berger R, Ross S, Rothman I, Muller C . Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia. J Androl. 1996; 17(3):310-8. View

19.

Pfau A . The treatment of chronic bacterial prostatitis. Infection. 1991; 19 Suppl 3:S160-4. DOI: 10.1007/BF01643689. View

20.

BARNES R, Daifuku R, Roddy R, Stamm W . Urinary-tract infection in sexually active homosexual men. Lancet. 1986; 1(8474):171-3. DOI: 10.1016/s0140-6736(86)90650-1. View